192069-76-4

Upstream product

• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 40878-11-3 [3-(3,4-dichloro-phenyl)-5-oxo-pyrrolidin-3-yl]-acetic acid ethyl ester 
• 40878-10-2 3-cyano-3-(3,4-dichloro-phenyl)-pentanedioic acid diethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 52423-89-9 3-(3,4-dichloro-phenyl)-3-(2-hydroxy-ethyl)-pyrrolidine 

Downstream Products

• 716327-30-9 1,1-dimethylethyl 3-(3,4-dichlorophenyl)-3-(3-oxopropyl)-1-pyrrolidinecarboxylate 

Relevant academic research and scientific papers

PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS

The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or trea

SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES

The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.

Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors

We have synthesized and identified MDL 105,212, a non-peptide tachykinin receptor antagonist that has high affinity for human NK1 ((IC50 = 3.11 nM) and NK2 (IC50 = 8.40 nM) receptors. The chemical synthesis of M